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Amyotrophic Lateral Sclerosis-Associated SOD1
Mutant Proteins Bind and Aggregate
with Bcl-2 in Spinal Cord Mitochondria
al., 1999) and of human ALS patients without SOD1
mutations (Martin, 1999; Ekegren et al., 1999). In several
different lines of ALS mice, several caspases are acti-
vated, including the upstream caspases 1 and 9 and the
downstream executioner caspases 3 and 7 (Pasinelli et
Piera Pasinelli,1,2,* Mary Elizabeth Belford,1,2
Niall Lennon,1,2 Brian J. Bacskai,2
Bradley T. Hyman,2 Davide Trotti,1,2
and Robert H. Brown, Jr.1,2,*
1Day Laboratory for Neuromuscular Research
al., 1998, 2000; Vukosavic et al., 2000; Li et al., 2000;2 Department of Neurology
Guegan et al., 2001; Guegan and Przedborski, 2003).Harvard Medical School
Release of cytochrome c from the mitochondria to theMass General Institute for Neurodegenerative
cytosol has been observed in spinal cords of SOD1G93ADisease
transgenic mice, linking mutSOD1-mediated toxicity toMassachusetts General Hospital
the mitochondrial apoptotic pathway (Guegan et al.,Charlestown, Massachusetts 02129
2001). In addition, survival of the SOD1G93A ALS mice is
prolonged by overexpression of Bcl-2 (Kostic et al., 1997),
by inhibition of caspase-1 (Friedlander et al., 1997), andSummary
by treatment with the pancaspase inhibitor ZVAD-fmk
(Li et al., 2000). Biochemical changes associated withFamilial amyotrophic lateral sclerosis (ALS)-linked muta-
apoptosis have recently been reported in postmortemtions in the copper-zinc superoxide dismutase (SOD1)
spinal cord tissues of ALS patients (Li et al., 2000; Ilzeckagene cause motor neuron death in about 3% of ALS
et al., 2001).cases. While the wild-type (wt) protein is anti-apo-
We have shown that an early event in mutSOD1-medi-ptotic, mutant SOD1 promotes apoptosis. We now
ated apoptosis is activation of caspase-1 (Pasinelli etdemonstrate that both wt and mutant SOD1 bind the
al., 2000). This is evident in the spinal cords of mice withanti-apoptotic protein Bcl-2, providing evidence of a
three different SOD1 mutant transgenes. In one line ofdirect link between SOD1 and an apoptotic pathway.
mice (SOD1G85R), caspase-1 activation is the earliest mo-This interaction is evident in vitro and in vivo in mouse
lecular abnormality detected to date. These findings sug-and human spinal cord. We also demonstrate that in
gest that in mutSOD1-mediated cell death, apoptosis ismice and humans, Bcl-2 binds to high molecular
a slowly evolving phenomenon that is directly triggeredweight SDS-resistant mutant SOD1 containing aggre-
by the mutSOD1 protein. This observation, and the strik-gates that are present in mitochondria from spinal
ing finding that SOD1WT protein is strongly anti-apo-cord but not liver. These findings provide new insights
ptotic, suggest that SOD1WT protects the cells againstinto the anti-apoptotic function of SOD1 and suggest
apoptosis either directly or indirectly by interacting withthat entrapment of Bcl-2 by large SOD1 aggregates
proteins that mediate programmed cell death, includingmay deplete motor neurons of this anti-apoptotic
members of the Bcl-2 family. The corollary predictionprotein.
is that mutSOD1 protein may acquire a pro-apoptotic
function by altering this interaction. An alternative modelIntroduction
is that SOD1WT exerts its anti-apoptotic function by act-
ing on the mitochondria and that mutSOD1 protein pro-Amyotrophic lateral sclerosis is a fatal paralytic disorder
motes cell death by an aberrant mitochondrial inter-characterized by selective death of motor neurons. About
action.3% of ALS cases are caused by mutations in the gene
Mitochondria are of particular interest in this context.
encoding copper-zinc superoxide dismutase (SOD1)
First, mitochondrial degeneration, vacuolization, and
(Rosen et al., 1993). More than 100 different mutations
swelling are characteristic pathological features in mut-
in SOD1 are known (Andersen et al., 2003). Mutant SOD1 SOD1 mice and in familial ALS cases (Dal Canto and
(mutSOD1)-mediated toxicity results from a gain of one Gurney, 1995; Wong et al., 1995; Kong and Xu, 1998).
or more toxic properties that are not fully delineated Second, mitochondria tightly control apoptosis, and
(Cleveland and Rothstein, 2001). mutSOD1-mediated toxicity entails activation of the mi-
While the wild-type (wt) SOD1 (SOD1WT) is anti-apo- tochondrial apoptotic pathway (Guegan et al., 2001).
ptotic in neuronal cultures and a determinant of lifespan Third, although it has been considered a cytosolic pro-
in Drosophila (Rothstein et al., 1994; Rabizadeh et al., tein, a fraction of SOD1 is localized in the mitochondria
1995; Greenlund et al., 1995; Parkes et al., 1998), mut- (Higgins et al., 2002; Okado-Matsumoto and Fridovich,
SOD1 proteins are pro-apoptotic both in vitro and in vivo 2002; Mattiazzi et al., 2002). Finally, mutSOD1 that is
(Durham et al., 1997; Rabizadeh et al., 1995; Ghadge et linked to mitochondria triggers apoptosis more strongly
al., 1997; Pasinelli et al., 1998, 2000). Thus, increased than the cytosolic mutant protein (Takeuchi et al., 2002).
expression of the pro-apoptotic proteins Bax and Bad To better characterize the mechanism by which SOD1
and decreased expression of the anti-apoptotic Bcl-2 regulates apoptosis and to test the models described
have been found in the spinal cord of transgenic mice above, we have studied apoptotic proteins that interact
expressing SOD1 with the G93A mutation (Vukosavic et with SOD1. We report here that the anti-apoptotic pro-
tein Bcl-2 interacts with both wt and mutSOD1. More-
over, we report binding of mutSOD1 to Bcl-2 in spinal*Correspondence: ppasinelli@partners.org (P.P.), rhbrown@partners.
org (R.H.B.) cord mitochondria. Finally, we demonstrate that in mice
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Figure 1. Wild-Type and mutSOD1 Copre-
cipitate with Bcl-2
(A) Co-immunoprecipitation was carried out
with the anti-mouse Bcl-2 antibody. Western
blot analysis of the immunoprecipitates using
the anti-human SOD1 antibody indicates that
Bcl-2 coprecipitates wt and mutSOD1s (G37R,
G41D, and G85R) (top). Bcl-2 immunoprecipi-
tation was confirmed by reprobing the mem-
brane with the anti-mouse Bcl-2 antibody
(bottom).
(B) The reverse immunoprecipitation was car-
ried out with the anti-human SOD1 antibody.
Western blot analysis with the anti-mouse
Bcl-2 antibody (left) confirms the interaction
between SOD1 and Bcl-2. The immunoblot
was stripped and reprobed for the precipitat-
ing SOD1 (right).
(C) The anti-mouse Bcl-2 antibody coprecipi-
tates the endogenous mouse SOD1 (top). The
immunoblot was stripped and reprobed for
the precipitating Bcl-2 (bottom).
(D) The anti-SOD1 antibody does not copre-
cipitate the anti-apoptotic protein Bax (top)
or Actin (bottom). Abbreviations: TL, total ly-
sates; hSOD1, human SOD1; msebcl-2, mouse
Bcl-2.
and human spinal cords, Bcl-2 binds to high molecular endogenous SOD1 and that the interaction is not an
artifact of overexpression of the human SOD1 protein,weight SDS-resistant mutSOD1-containing aggregates
that are present in spinal cord but not liver mitochondria. we incubated lysates from naive, nontransfected N2A
cells with the anti-mouse Bcl-2 antibody. The immuno-These observations suggest the hypothesis that mutant
protein captures Bcl-2 within unstable aggregates, de- precipitate was analyzed by Western blot for the pres-
ence of the endogenous mouse SOD1. Figure 1C (top)pleting the motor neurons of this anti-apoptotic protein.
shows that the anti-Bcl-2 antibody coprecipitated en-
dogenous mouse SOD1. Bcl-2 immunoprecipitation wasResults
confirmed by restaining the same blot with anti-mouse
Bcl-2 antibody (Figure 1C, bottom). This result confirmsWild-Type and Mutant SOD1 Associate with Bcl-2
the positive immunostaining for both human and mousePostnuclear homogenates from N2A cells transfected
SOD1 that we have observed in the immunoprecipitateswith either the wt human SOD1 or three different mutants
shown in Figure 1A and clearly shows that endogenous(G37R, G41D, and G85R) were subjected to immunopre-
SOD1 associates with endogenous Bcl-2.cipitation using an anti-mouse Bcl-2 antibody. Western
To demonstrate the specificity of the interaction be-blot analysis of immunoprecipitated proteins revealed
tween SOD1 and Bcl-2, we performed co-immunopre-that both wt and mutSOD1s were coprecipitated by the
cipitation experiments with the anti-human SOD1 anti-anti-mouse Bcl-2 antibody (Figure 1A, top), indicating a
body and analyzed the resulting immunoprecipitates byphysical interaction between SOD1 and Bcl-2. The N2A
Western blot with an anti-Bax and an anti-Actin antibodycells also express the endogenous mouse SOD1. Be-
as negative controls. Lysates from wt human SOD1-cause human SOD1 has a slower electrophoretic mobil-
expressing N2A cells were immunoprecipitated fority than mouse SOD1, the two proteins are easily distin-
SOD1. Bax and Actin were not immunodetected in theguishable on Western blots. As shown in Figure 1A (top),
immunoprecipitates but were present in the straight ly-the anti-Bcl-2 antibody coprecipitates both the human
sates (Figure 1D). Similarly, the anti-mouse Bcl-2 anti-SOD1 and the endogenous mouse protein. When the
body was unable to precipitate Actin (data not shown).same blot was immunostained with an anti-Bcl-2 anti-
body, a single band of about 26 kDa corresponding to
the endogenous mouse Bcl-2 was detected, indicating SOD1 and Bcl-2 Interact In Vivo in Spinal Cord
of Transgenic SOD1 Mice and in Humanthat Bcl-2 was successfully immunoprecipitated (Figure
1A, bottom). To confirm the binding between SOD1 and Spinal Cords
We confirmed the physical interaction between SOD1Bcl-2, we performed the reverse experiment in hSOD1WT-
expressing cells. The presence of Bcl-2 in the SOD1 and Bcl-2 in spinal cord homogenates of transgenic
SOD1 mice overexpressing either wt human SOD1 orimmunoprecipitate was shown by Western blot analysis
(Figure 1B, left), and SOD1 immunoprecipitation was G93A mutant SOD1 and in human spinal cord homoge-
nates. Spinal cord homogenates from presymptomaticconfirmed on the same blot restained with the anti-
human SOD1 antibody (Figure 1B, right). G93A ALS mice and age-matched transgenic mice over-
expressing human SOD1WT were subjected to immu-To verify that endogenous Bcl-2 can associate with
Mutant SOD1 Aggregates with Bcl-2 in Mitochondria
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and SOD1, respectively (Figure 3B, bottom). Western
blot replicas of the second dimension showed that the
26 and the 17–20 kDa positively immunostained with
the anti-mouse Bcl-2 and with the anti-SOD1 antibody,
respectively (Figure 3B, top), confirming the results ob-
tained by silver staining. Similar results were obtained
from crosslinking of lysates of cells expressing two dif-
ferent SOD1 mutants (G37R and G41D) (data not shown).
We cannot exclude the formal possibility that crosslink-
ing in these experiments is between Bcl-2 or SOD1 itself;
indeed, it is well established that SOD1 homodimerizes.
However, these crosslinking experiments are fully con-
sistent with complex formation between Bcl-2 and SOD1Figure 2. SOD1 and Bcl-2 Interact In Vivo in Mouse and Human
as suggested by the co-immunoprecipitation experi-Spinal Cords
ments above. Our next experiments provide additional(A) Spinal cord homogenates from presymptomatic (45 days old)
support for this direct interaction.SOD1G93A mice and age-matched hSOD1WT overexpressing mice
were subjected to immunoprecipitation using the anti-mouse Bcl-2
antibody. Blots were probed with the anti-human SOD1 antibody Fluorescence Lifetime Imaging Microscopy
(left) and subsequently the anti-mouse Bcl-2 antibody (right). Analysis Confirms that SOD1 and Bcl-2(B) Coprecipitation experiments were performed in human spinal
Interact in the N2A Cellscord homogenates with the anti-human Bcl-2 antibody. Bcl-2 pre-
In these experiments, fluorescence lifetime imagingcipitates stained positive for SOD1. Abbreviations: hSOD1, human
SOD1; msebcl-2, mouse Bcl-2. microscopy (FLIM) was used to monitor fluorescence
resonance energy transfer (FRET) between fluorescein-
labeled Bcl-2 (donor) and Cy3-labeled SOD1 (acceptor)
noprecipitation using the anti-mouse Bcl-2 antibody. in human SOD1WT-expressing N2A cells. In cells, if pro-
Western blot analysis confirmed the presence of both tein-linked donor and acceptor fluorophores are in close
human and mouse SOD1 in the precipitates (Figure 2A, proximity, FRET causes a reduction in the lifetime () of
left) and confirmed that Bcl-2 was successfully precipi- the fluorescence of the donor. FLIM allows detection of
tated (Figure 2A, right). We then carried out a co-immu- protein-protein interaction on a spatial scale (less than
noprecipitation experiment in human spinal cords. Spi- 10 nm) (Bacskai et al., 2003). The lifetime of fluorescein-
nal cord homogenates from human samples were conjugated secondary antibody to bind the primary anti-
immunoprecipitated with an anti-human Bcl-2 antibody. Bcl-2 antibody was calculated to be 2.1 0.18 ns (Figure
Western blot analysis confirmed the presence of a posi- 3C). This was shortened to 1.09 0.3 ns by the presence
tive SOD1 immunoreactive band in the precipitates (Fig- of the Cy3-conjugated secondary antibody bound to the
ure 2B). anti-SOD1 primary antibody (Figure 3C), indicating that
there is significant energy transfer (FRET) between the
donor and the acceptor fluorophore because of the veryCrosslinking Studies Show Formation of High
close spatial interaction between SOD1 and Bcl-2. ByMolecular Mass Complexes Containing
contrast, when the Cy-3 antibody was bound to the anti-SOD1 and Bcl-2
COX4 antibody to stain the mitochondria, there was noTo validate our findings, we performed crosslinking ex-
FLIM-detectable association between Bcl-2 and COX4periments followed by off-diagonal two-dimensional (2D)
(Figure 3C). In vivo, double immunofluorescence experi-electrophoresis. Lysates from human SOD1WT-express-
ments revealed that SOD1 and Bcl-2 colocalize exten-ing N2A cells were incubated with the hydrophobic
sively in the anterior horn motor neurons of presymp-crosslinker DSP that allows analysis of intra- and inter-
tomatic SOD1G93A mice (not shown).membrane interactions. DSP is a thiol-cleavable, 12 A˚
crosslinker routinely used in 2D nonreducing/reducing
diagonal gels. In this system, DSP-linked stabilized SOD1 Directly Interacts with Bcl-2
To determine whether SOD1 directly binds to Bcl-2, wemembrane complexes are first separated according to
their electrophoretic mobility under nonreducing condi- performed coprecipitation experiments using in vitro
translated proteins. Bcl-2 cDNA as well as SOD1 cDNAstions. The first dimension lanes are then cut from the
gel, reduced to cleave the crosslinked covalent bonds, (wt and G93A) were translated in vitro as described.
Figure 4 shows in vitro translated products of Bcl-2and overlaid on top of the second dimension slab gel.
Previously crosslinked complexes are identified as sin- (lane 1, left) and SOD1WT (lane 1, middle). As shown,
[35S]methionine radiolabeled Bcl-2 was first visualized bygle dots that run off the diagonal. In the first dimension,
increasing concentrations of crosslinker enhanced the autoradiography. Because it lacks methionines, SOD1
cannot be detected by autoradiography. We thereforeappearance of high molecular mass complexes that
stained positive on Western immunoblots for both Bcl-2 analyzed translation of the SOD1 protein by Western
immunoblotting. Portions of the translated proteins were(Figure 3A, left) and SOD1 (Figure 3A, right). Silver stain-
ing of the second dimension run under reducing condi- immunoprecipitated with the indicated antibodies. In
the absence of SOD1 protein, the anti-human SOD1tions showed two dots coming off the diagonal and
migrating on the same vertical line. One dot migrated antibody was not able to immunoprecipitate in vitro
translated Bcl-2 (Figure 4, left, lane 2), indicating thatat about 26 kDa and the other migrated at about 17–20
kDa, corresponding to the molecular weights of Bcl-2 the SOD1-specific antibody does not directly bind to
Neuron
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Figure 3. Crosslinking Analysis and Off Diag-
onal 2D Electrophoresis
(A and B) Crosslinking reaction was per-
formed on N2A cell lysates, and samples were
resolved on SDS-PAGE under (A) nonreduc-
ing (first dimension) and (B) reducing (second
dimension) conditions. For the first dimen-
sion, the appearance of high molecular mass
complexes was detected with both the anti-
mouse Bcl-2 antibody (A, left) and anti-human
SOD1 antibody (A, right). Western blot (B, top)
and silver stain (B, bottom) analysis of the
second dimension.
(C) FLIM was undertaken to determine the
amount of FRET between FITC-labeled Bcl-2
(donor) and Cy3-labeled SOD1 or Cy3-labeled
COX4 (acceptor). Data are mean  SD of
three independent observations. **p  0.001.
Bcl-2 and therefore does not nonspecifically precipi- Wild-Type SOD1 Binds the N-Terminal Domain
of Bcl-2, and Mutations in SOD1 Altertate Bcl-2. Similarly, in the absence of Bcl-2, the anti-
human Bcl-2 antibody was not able to immunoprecipi- This Binding
To determine the regions of Bcl-2 that are required fortate SOD1 (Figure 4, middle, lane 2), while it successfully
precipitated Bcl-2 (Figure 4, left, lane 3). This confirms specific binding to SOD1, we used a panel of human
Bcl-2 mutants (generous gift from Dr. Stanley Kors-the specificity of our previous coprecipitation experi-
ments. When the anti-human SOD1 antibody was used meyer). These include four deletion mutants (BH4,
loop, TM, and BH4/loop, lacking the BH4, loop,to precipitate mixed portions of the two in vitro trans-
lated proteins, Bcl-2 was detected, confirming that transmembrane, and BH4loop domain, respectively)
(Figure 5A). Using these mutants, we examined the re-SOD1 directly interacts with Bcl-2 (Figure 4, left, lane
4). Similarly, when mixed portions of translated human gions of human Bcl-2 important for binding to SOD1 by
co-immunoprecipitation of in vitro translated proteins.Bcl-2 and G93A mutant were precipitated with the anti-
human Bcl-2 antibody, the mutSOD1 was detected with We mixed in vitro translated Bcl-2 mutants with either
in vitro translated wt or SOD1G93A mutant and performedthe anti-human SOD1 antibody (Figure 4, right). We con-
firmed the specificity of these immunoprecipitations by co-immunoprecipitation experiments with anti-human
Bcl-2 antibody. Immunoprecipitates were analyzed byco-expressing FLAG-tagged human Bcl-2 and untagged
human SOD1 in Xenopus laevis oocytes. The anti-FLAG Western blot using the anti-human SOD1 antibody.
SOD1WT coprecipitates with loop, BH4, TM, and wtantibody successfully pulled down human SOD1 (not
shown). Bcl-2 to the same extent. In contrast, the BH4/loop
Figure 4. SOD1 and Bcl-2 Directly Interact
In Vitro
Bcl-2 cDNA and SOD1 cDNAs (wt and G93A)
were in vitro translated as described and pro-
teins were analyzed either by autoradiogra-
phy (Bcl-2, left) or by Western blot analysis
(SOD1, middle and right). In vitro translated
products of wt Bcl-2 (lane 1, left) and SOD1WT
(lane 1, middle) are shown. To determine the
specificity of either the anti-human Bcl-2 or
the anti-human SOD1 antibody in immuno-
precipitation, portions of the translated pro-
teins (wt Bcl-2 and SOD1) were immunopre-
cipitated with anti-human SOD1 antibody or
anti-human Bcl-2 antibody. The anti-SOD1
antibody did not precipitate human Bcl-2
(lane 2, left), and the anti-human Bcl-2 anti-
body failed to precipitate SOD1 (lane 2, middle). Mixed portions of the two in vitro translated proteins were positively immunoprecipitated by
the anti-SOD1 antibody (lane 4, left) or the anti-Bcl-2 antibody (right). Abbreviation: IVT, in vitro translation.
Mutant SOD1 Aggregates with Bcl-2 in Mitochondria
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Figure 5. Wild-Type SOD1 Binds the N-Terminal Domain of Bcl-2
(A) A diagram of the Bcl-2 deletion mutants used is represented in the left panel. Right: In vitro translated wt or Bcl-2 mutants and wt or
SOD1G93A mutant were mixed and immunoprecipitated with the anti-Bcl-2 antibody. Immunoprecipitates were analyzed by Western blot with
the anti-SOD1 antibody.
(B) FLAG-tagged Bcl-2 and untagged SOD1 were co-expressed in Xenopus oocytes. The upper gel shows Western blot analysis of hSOD1
after immunoprecipitation with the anti-FLAG antibody. The lower picture shows Western blot analysis of hSOD1 in the total lysates to verify
that SOD1 is expressed in oocytes.
(C) Bcl-2 deletion mutants and mutSOD1 cDNAs were in vitro translated. Mixed portions of translated proteins were immunoprecipitated with
the anti-hSOD1 antibody. Western blot was analyzed with the anti-FLAG antibody.
double deletion abolishes the interaction (Figure 5A, retained their binding ability (Figure 5B, left), confirming
the in vitro experiments described above.right), indicating that the region between the BH4 and
the loop domain of Bcl-2 is essential for the binding We further confirmed the generality of these findings
using three other mutSOD1s (A4V, I113T, and H46R).with SOD1WT. However, the BH4/loop double deletion
does not abolish the binding with SOD1G93A mutant. In In the first set of experiments, we mixed the in vitro
translated FLAG-tagged BH4 and BH4/loop Bcl-2fact, SOD1G93A coprecipitates with all four Bcl-2 deletion
mutants and wt Bcl-2 to a similar extent (Figure 5A, mutants with in vitro translated SOD1s (wt, A4V, I113T,
G93A, and H46R) and performed co-immunoprecipita-right). We also used two different mutants with single
point mutations in the BH1 and BH2 domains. These tion experiments using the anti-human SOD1 antibody.
Analysis of the resulting immunoprecipitates with thepoint mutations abolish binding of Bcl-2 with other pro-
teins (Yin et al., 1994; Sedlak et al., 1995). None of these anti-FLAG antibody confirmed our previous findings; all
mutSOD1s equally coprecipitated withBH4 andBH4/Bcl-2 point mutations abolished the binding with either
wt or SOD1G93A mutant (not shown). These data indicate loop Bcl-2, while this double Bcl-2 deletion greatly
reduced the binding with SOD1WT (Figure 5C).that the region between the BH4 and the loop domain
in Bcl-2 is required for the binding with SOD1 and that
mutations in SOD1 alter this binding. Mutant SOD1 Forms SDS-Resistant High Molecular
Weight Aggregates that PreferentiallyTo confirm that the different binding to Bcl-2 observed
between wt and mutSOD1 also occurs in a cellular sys- Bind to Spinal Cord Mitochondria
and Coprecipitate with Bcl-2tem in which proteins are properly folded and targeted
to the correct intracellular compartment, we used the We next analyzed whether mutations in SOD1 affect the
interaction with Bcl-2 in vivo during disease progressionXenopus laevis oocytes expression system. Two FLAG-
tagged Bcl-2 mutants (BH4 and BH4/loop double in the SOD1G93A mice and in human ALS. Spinal cord
homogenates from either ALS mice or mice overexpress-deletion) were co-expressed in oocytes with human
SOD1 (wt and G93A). When the BH4 deletion mutant ing SOD1WT were subjected to immunoprecipitation us-
ing the anti-mouse Bcl-2 antibody. Immunoprecipitateswas co-expressed with SOD1WT, the anti-FLAG antibody
was able to coprecipitate SOD1, while the BH4/loop were analyzed by Western blot using the anti-human SOD1
antibody. As the disease progressed in the SOD1G93A mice,double deletion mutant abolished or greatly reduced the
interaction with SOD1 (Figure 5B, left). On the contrary, there was a gradual increase in the amount of SOD1 co-
immunoprecipitated by the anti-Bcl-2 antibody. Whenwhen co-expressed with SOD1G93A, both Bcl-2 mutants
Neuron
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Figure 6. Bcl-2 Binds SDS-Resistant High Molecular Weight SOD1 Aggregates
(A) Spinal cord homogenates from SOD1G93A and hSOD1WT overexpressing mice were subjected to immunoprecipitation using the anti-Bcl-2
antibody, and precipitated samples were analyzed by Western blot using the anti-human SOD1 antibody. Left upper panel shows samples
from presymptomatic (PS), early onset (OS), or end stage (ES) ALS mice and 140-day-old hSOD1WT overexpressing mice (age-matched with
the end stage ALS mice). Left lower panel shows Western blot analysis of total lysates derived from the same mice stained with the anti-
human SOD1 antibody and overexposed to detect the appearance of SDS-resistant high molecular weight aggregates (asterisks). Right panel
shows Western blot analysis of total lysates derived from the same mice to confirm equal expression of SOD1 and Bcl-2 over time. Densitometric
analysis was performed for each blot and is summarized in the histogram below each blot.
(B) Human spinal cord homogenates were subjected to immunoprecipitation using an anti-human Bcl-2 antibody and samples analyzed by
Western blot with the anti-human SOD1 antibody. Compared to non-ALS and sporadic controls, the SOD1-A4V ALS sample showed a stronger
binding between SOD1 and Bcl-2 (see densitometric analysis below), and the Bcl-2 antibody coprecipitated high molecular weight SDS-
resistant A4V containing aggregates (asterisks).
compared to that of presymptomatic mice, the amount ALS patient carrying the A4V mutation. The amount of
SOD1 coprecipitated by the Bcl-2 antibody is about 1.5-of SOD1 precipitated by the anti-Bcl-2 antibody is 1.8-
and 2.1-fold higher at the time of onset and end stage, fold higher in the SOD1-ALS patient than in a sporadic
patient and non-ALS control (Figure 6B, left). Moreover,respectively (Figure 6A, histogram). This is not due to
an increase in overall SOD1 expression, since equal the anti-human Bcl-2 antibody is able to coprecipitate
high molecular weight A4V-containing aggregates asSOD1 expression is detected among the different ani-
mals (Figure 6A, upper right). This is also not due to an observed in the mice. Bcl-2 is entrapped in these high
molecular weight aggregates that stain positive for theincrease over time in Bcl-2 expression, because in fact
this decreases as disease progresses (Figure 6A, lower anti-Bcl-2 antibody (Figure 6B, right).
We next determined whether the SOD1/Bcl-2-con-right; Vukosavic et al., 1999). At the time of onset, and
more at end stage, Bcl-2 binds high molecular weight taining aggregates are present in the mitochondria.
Bcl-2 is a membrane protein found in mitochondria, ER,SDS-resistant SOD1 aggregates (Figure 6A, left, aster-
isks). The time course of appearance of these precipi- and nuclei. A single transmembrane domain at the car-
boxyl terminus anchors Bcl-2 to the mitochondrial mem-tated aggregates and their levels of expression correlate
with that of high molecular weight complexes that are brane while the majority of the protein faces the cytosol
(Schimmer et al., 2001). Based on our in vitro experi-present in the total lysates of these mice after a pro-
longed exposure of the blot (Figure 6A, lower left). As ments with Bcl-2 deletion mutants, we predicted that
while SOD1WT binds the cytosolic portion of Bcl-2, mut-shown, the high molecular weight aggregates are hardly
detectable in total lysates at the time of onset. However, SOD1 binds at or near the mitochondrial membrane.
A corollary prediction is that the mutSOD1 protein isthe fact that they are precipitated with the Bcl-2 antibody
strongly indicates that they tightly bind to Bcl-2. associated with the mitochondrion more tightly than
SOD1WT during mitochondrial purification. Accordingly,Bcl-2 binding to large mutSOD1-containing aggre-
gates is also observed in spinal cord homogenate of an when we isolated mitochondria from mouse and human
Mutant SOD1 Aggregates with Bcl-2 in Mitochondria
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Figure 7. Mutant SOD1 Specifically Binds
Bcl-2 in the Mitochondria
(A) Mitochondria purified from spinal cord
and liver of 133-day-old naive (NV), hSOD1WT
(wt), and SOD1G93A transgenic mice were incu-
bated with the anti-mouse Bcl-2 antibody,
and samples were analyzed by Western blot
with the anti-human SOD1 antibody. The pre-
cipitating Bcl-2 was analyzed by Western blot
using an anti-mouse Bcl-2 antibody (bottom).
(B) Immunoprecipitation with the anti-human
Bcl-2 antibody was performed using human
purified mitochondria. Immunoprecipitates were
analyzed by Western blot. The left panel
shows a representative Western blot of Bcl-2
precipitates from spinal cord mitochondria
probed with the anti-human SOD1 antibody.
The right panel shows a comparison of Bcl-2
precipitates from spinal cord and liver mito-
chondria isolated from a FALS-A4V patient.
Western blot was probed with the anti-human
SOD1 antibody.
(C) 10g of spinal cord and liver mitochondria
isolated from SOD1G93A mice (left) and FALS-
A4V patient (right) were resolved on SDS-
PAGE, transferred to nitrocellulose, and blot-
ted with the anti-human SOD1 antibody.
Asterisks indicate high molecular weight
SDS-resistant SOD1 containing aggregates.
Abbreviations: SC, spinal cord; LV, liver.
spinal cords, we found that the anti-Bcl-2 antibody co- associated with failure of astroglial glutamate transport
(Rothstein et al., 1990), perturbed oxidative metabolismprecipitated only mutant but not SOD1WT (Figures 7A and
7B), even though Bcl-2 was successfully precipitated in as measured by levels of diverse oxidative species, and
gradual failure of energy generation and mitochondrialall mouse samples (Figure 7A, bottom). Together with
monomeric SOD1, the Bcl-2 antibody coprecipitated function (Bowling et al., 1993). Despite intensive investi-
gation, the mechanisms whereby mutSOD1 protein trig-high molecular weight SDS-resistant aggregates con-
taining mutSOD1 (Figures 7A and 7B). Moreover, these gers and sustains these events has remained elusive.
Equally problematic has been the explanation for howaggregated forms of mutSOD1 were pulled down with
the anti-Bcl-2 antibody in spinal cord but not in liver mutations in a ubiquitously expressed and abundant
protein produce a cell death process that is so exqui-mitochondria (Figures 7A and 7B). These results are not
a consequence of different levels of SOD1 expression sitely motor neuron specific.
in these tissues, as SOD1 is equivalently expressed in The present study provides new insight into these
spinal cord and liver mitochondria (Figure 7C). However, questions by delineating a direct binding interaction be-
they suggest a correlation between the motor neuron tween wt or mutSOD1 and the anti-apoptotic protein
phenotype of the disease and the formation of the SOD1/ Bcl-2. This interaction is readily demonstrated both
Bcl-2-containing aggregates. We note that high molecu- in vitro and in vivo in mouse and human spinal cords. The
lar weight SDS-resistant SOD1- and Bcl-2-positive ag- binding is specific; neither Actin nor the pro-apoptotic
gregates similar to those in human A4V and mouse G93A protein Bax co-immunoprecipitate with SOD1. Our data
spinal cord mitochondria were also detected in spinal show that ALS-associated mutSOD1 protein binds av-
cord mitochondria from SOD1G37R transgenic ALS mice idly to mitochondria with which it forms SDS-resistant
(Supplemental Figure S1 at http://www.neuron.org/cgi/ aggregates that, in turn, are bound by and contain Bcl-2.
content/full/43/1/19/DC1). We also report comparable association between SOD1/
Bcl-2-positive aggregates and mitochondria in the spi-
nal cord of a patient who succumbed to familial ALSDiscussion
caused by the very common alanine-4-valine mutation.
In our view, it is striking that both in the ALS mice andIn transgenic ALS mice, it is evident that multiple pro-
FALS-A4V patient, these SOD1/Bcl-2-containing aggre-cesses converge to reduce motor neuron viability in an
gates are readily detected in spinal cord mitochondriaage-dependent manner. As gauged temporally, these
but are absent in liver mitochondria. These observationsinclude early mitochondrial vacuolization (Wong et al.,
argue that one important mechanism for the neurotoxic-1995), activation of microglial proliferation, and concom-
ity of mutSOD1 protein may derive from adverse conse-itant activation of caspase-1 (Pasinelli et al., 2000). Later
quences of this mutant protein on the function of Bcl-2stages entail aggregation of mutSOD1 protein (Bruijn et
and mitochondria. Figure 8 summarizes these findings.al., 1998), activation of caspase-3 (Pasinelli et al., 2000),
That mitochondrial pathology is an essential elementand motor neuronal cell death. These events unfold in
the setting of enhanced sensitivity to excitotoxic stimuli in neuronal cell death in transgenic ALS mice seems
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dria via the activity of the respiratory chain complexes.
The route of entry and process by which cytosolic SOD1
is imported into mitochondria are not known. Nonethe-
less, these studies collectively raise the hypothesis that
an important element in mitochondrial dysfunction in
the ALS mice is the intimate spatial relationship between
this organelle and mutSOD1 protein.
The present study reveals that at least one pathway
whereby SOD1 interacts with the mitochondrion is by
binding and docking to Bcl-2. In vitro, this is evident
with both wt and mutSOD1. This observation is compati-
ble with reports that wt and mutSOD1 can enter the
mitochondrion (Mattiazzi et al., 2002; Okado-Matsumoto
and Fridovich, 2002). Moreover, this finding potentially
provides a link between a normal docking function and
the evolution of mitochondrial pathology. It is clear from
numerous studies that one pathogenic feature of mu-
tated SOD1 is diminished protein stability and a procliv-
ity to aggregate (Cleveland and Rothstein, 2001). We
now report that aggregates of SOD1 are abundant andFigure 8. Schematic Model of the SOD1/Bcl-2 Interaction
readily detected in spinal cord mitochondria. It is plausi-Top: SOD1WT binds to the N-terminal domain of Bcl-2 that is located
ble that the localization of SOD1 to the mitochondrionin the cytosol. Our data indicate that the binding is disrupted during
mitochondria isolation. Bottom: The unstable mutant SOD1 protein via the Bcl-2 interaction, either on the outside or just
forms insoluble aggregates that bind Bcl-2 and are strongly associ- within the outer membrane, positions the mutant protein
ated with the outer membrane of the mitochondria. mutSOD1 is to aggregate in a manner that is toxic to the mitochon-
present in purified mitochondria under the same preparative condi-
drion. We note that other groups have also describedtions used for SOD1WT. The high molecular weight mutSOD1/Bcl-2
high molecular weight species of mutSOD1 protein inaggregates are present in spinal cord mitochondria but not liver mi-
mitochondria (Mattiazzi et al., 2002).tochondria.
Moreover, these findings point to a link between the
pattern of mitochondrial SOD1 aggregation and the mo-irrefutable. As assessed by both functional and morpho-
tor neuron focus of ALS. For reasons that are not clearlogical criteria, mitochondrial damage is a characteristic
as yet, the process of accumulation of aggregates infeature of motor neuron degeneration mediated by mut-
mitochondria is evident in spinal cord but not liver mito-SOD1 protein. In ALS transgenic mice, mitochondrial
chondria. To the extent that aggregates or proto-aggre-degeneration and vacuolization are among the earliest
gates of mutSOD1 are toxic to mitochondria, this prefer-abnormalities, detected well before signs of clinical mo-
ential aggregation of SOD1 in spinal cord but not liver
tor weakness; the peak of this vacuolization coincides
mitochondria defines a potential Achilles’ heel that may
with onset of weakness in the G93A transgenic mice
render spinal cord cells susceptible to this mutant pro-
(Wong et al., 1995; Kong and Xu, 1998). Biochemical
tein. These studies are consonant with recent data dem-
analyses document that mitochondrial respiratory chain onstrating that mutant but not SOD1WT specifically local-
activity and ATP generation are diminished in the pres- izes to spinal cord mitochondria of ALS mice and
ence of mutSOD1 (Mattiazzi et al., 2002). As estimated patients (D.W. Cleveland, International ALS/MND meet-
histochemically, electron transport function is reduced ing, Milan, Italy, 2003).
in the ALS mice, specifically in the ventral horns (Higgins We note that by contrast with our findings, Mattiazzi
et al., 2002). Furthermore, there is evidence that calcium and colleagues reported that both wt and mutSOD1
homeostasis and membrane potential are significantly bind to the intermembrane space of the mitochondria
perturbed in mitochondria from the ALS mice (Appel et (Mattiazzi et al., 2002). We have found that SOD1WT binds
al., 2001). That mitochondria are particularly sensitive to Bcl-2 but do not find evidence that the wt molecule
to the presence of mutSOD1 has been confirmed in is present in isolated mitochondria. We think that this
quantitative estimates of cell death arising from tar- discrepancy reflects differences in our assays. Because
geting of SOD1 specifically to the nucleus, cytosol, and our detection system required immunoprecipitation, we
mitochondrion (Takeuchi et al., 2002). should have detected even minute amounts of residual
The mechanism for the particular susceptibility of mi- SOD1WT in the purified mitochondria. The failure to do
tochondria to mutSOD1 has not been explained. An im- so strongly suggests that SOD1WT is not present in the
portant clue is provided by several studies in the last isolated mitochondrion. It is conceivable that less strin-
five years showing that in yeast, mice, and rats, a fraction gent systems for the purification of the mitochondrion
of the normally cytosolic SOD1 protein is detected within and detection of the SOD1/Bcl-2 interaction may entail
the mitochondrion, probably either at the surface of this residual contamination by cytosolic SOD1.
organelle or within its intermembrane space (Sturtz et How do the mitochondrial mutSOD1/Bcl-2-containing
al., 2001; Higgins et al., 2002; Okado-Matsumoto and aggregates cause toxicity? Bcl-2 is a major regulator of
Fridovich, 2002; Mattiazzi et al., 2002). From an evolu- mitochondrial integrity and mitochondrial-initiated cas-
tionary perspective, this is not surprising given that the pase activation. Two important functions have been pro-
primary cellular site for the generation of superoxide posed for Bcl-2 in the mitochondria: the regulation of
the mitochondrial membrane potential and the bindinganion, the substrate of SOD1, is in the outer mitochon-
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and inhibition of pro-apoptotic proteins (Danial and leaving the majority of the protein reaching into the cyto-
Korsmeyer, 2004). It is known that protein-protein inter- sol. Our in vitro data with Bcl-2 deletion mutants show
actions play an important role in the function of Bcl-2. that SOD1WT binds the cytosolic portion of Bcl-2. In vivo,
Members of the Bcl-2 family regulate apoptosis either the ionic strength of the mitochondria isolation buffer is
through homodimerization, heterodimerization with pro- sufficient to disrupt this binding. On the contrary, the
teins in the same family, or binding with other protein binding between mutSOD1 and Bcl-2 is stable in the
partners. One possible consequence of the binding of same buffer. Moreover, our data suggest that mutSOD1
Bcl-2 to SOD1 may be that Bcl-2 itself will effectively be does not exclusively bind the N terminus. Because we
entrapped and rendered nonfunctional as the mutSOD1 find mutSOD1 in the purified, isolated mitochondria, we
protein aggregates. To the extent that Bcl-2 also actively believe that the mutated protein binds the carboxy-ter-
binds other anti-apoptotic proteins, this process of seg- minal domain of Bcl-2. Whether such docking is required
regation may further render the mitochondrion and its for subsequent translocation into the mitochondrion and
host cell less viable. This proposal is analogous to the the mechanism of translocation are not known. Okado-
suggestion that aggregated SOD1 might serve as a sink Matsumoto and Fridovich reported that in mouse neuro-
for heat shock proteins, thereby increasing the pro-apo- blastoma N2A cells, the entry of both wt and mutSOD1
ptotic state of the mitochondrion (Okado-Matsumoto into the mitochondria depends on demetallation. While
and Fridovich, 2002). Entrapment of Bcl-2 into mutSOD1 partially or fully demetallated SOD1 is integrated into
aggregates may also inhibit heterodimerization of Bcl-2 the mitochondrion, the holoenzyme is not. Noted in this
with pro-apoptotic molecules, a process that normally context are reports that demetallation of mutSOD1 ac-
blocks apoptosis. We note that in isolated mitochondria centuates its neurotoxic properties in neurons in vitro
from the spinal cord of an A4V ALS patient, coprecipi- (Estevez et al., 1999). Conceivably, our observation that
tates of mutSOD1 and Bcl-2 do not contain the pro- in ALS patients and transgenic ALS mice only the mutant
apoptotic protein Bax (unpublished observations). Pub- protein enters the mitochondrion may reflect the fact
lished data are consistent with the idea that entrapped that only the mutant protein is sufficiently conformation-
Bcl-2 cannot form Bcl-2/Bax heterodimers that normally ally unstable to lose metals.
block Bax pro-apoptotic function. In the SOD1G93A mice, Like Bcl-2, SOD1WT is anti-apoptotic in neurons. SOD1
Bcl-2 expression decreases during the course of the delays neuronal apoptosis in cultured sympathetic neu-
disease; this parallels an increase in Bax expression rons (Greenlund et al., 1995). Downregulation of SOD1
and a decrease in Bcl-2/Bax heterodimers (Vukosavic expression in cultured spinal motor neurons provokes
et al., 1999). apoptotic cell death and it enhances the sensitivity of
This hypothesis is consonant with studies document- PC12 and immortalized rat nigral neuronal cells to vari-
ing that Bcl-2 is a prosurvival protein that is required by ous apoptotic stimuli (Rothstein et al., 1994; Troy and
mature motor neurons (Michaelidis et al., 1996). In mice Shelanski, 1994). Similarly, primary motor neurons de-
with genetically inactivated Bcl-2, developmental loss of rived from SOD1 knockout mice undergo apoptosis and
motor neurons by apoptosis occurs normally. However, exhibit enhanced cell death after axonal injury. Because
after early periods of fetal development, these mice SOD1 represents one of the major anti-oxidant defenses
show accelerated death of motor and sensory neurons. in the cells and production of reactive oxygen species
This indicates that other anti-apoptotic members of the (ROS) and oxidative stress have been implicated in apo-
Bcl-2 gene family do not fully compensate for the ab- ptosis, the anti-apoptotic properties of SOD1 have
sence of Bcl-2. The fact that total loss of Bcl-2 causes mainly been attributed to its anti-oxidant activity. A fun-
death of both motor and sensory neurons, while mut- damental question that therefore follows from this study
SOD1 initiates selective motor neuron death, may reflect is whether the anti-apoptotic properties of SOD1 are a
two points. First, the mutSOD1-dependent reduction in consequence of both its dismutase/anti-oxidant func-
Bcl-2 is partial and slowly progressive. Second, motor
tion and, in parallel but perhaps independently, its inter-
neurons at baseline show reduced expression of Bcl-2
action with Bcl-2. That the dismutation function of SOD1
compared to sympathetic and sensory neurons (Yachnis
can be dissociated from its anti-apoptotic properties iset al., 1998) and thus may be more sensitive to partial
clear from studies showing that different mutant allelesloss of Bcl-2. Taking these considerations together, we
of SOD1 retain nearly normal dismutation activity butfind it plausible that mutSOD1-related reduction in levels
are pro-apoptotic in cells in culture (Pasinelli et al., 1998).of Bcl-2 can compromise motor neuron viability.
This is consistent with the report that injection of SOD1WTAnother possible consequence of the binding of mut-
or Bcl-2 expression vectors into immortalized rat nigralSOD1 to Bcl-2 is that this interaction may induce a con-
neuronal cells delayed apoptosis induced by NGF with-formational change that converts Bcl-2 into a pro-apo-
drawal but did not completely block cell death, evenptotic molecule. This mechanism is suggested by the
though SOD1 expression blocked ROS formation (Rabi-recent report that an interaction between the nuclear
zadeh et al., 1995). The implication, therefore, is thatorphan receptor Nur77/TR3 and Bcl-2 induces confor-
the anti-apoptotic function of SOD1WT is likely to reflectmational modifications of Bcl-2 that convert it into a
some other activity. We raise the possibility that onekiller protein (Lin et al., 2004).
such activity is the binding of SOD1 to the best-definedDetails of the biophysical nature of the SOD1-Bcl-2
anti-apoptotic protein, Bcl-2. An intriguing reciprocalinteraction await further analysis. As noted, our experi-
question is whether the anti-apoptotic properties ofments strongly indicate that mutSOD1 is associated with
Bcl-2 are in some way contingent on its binding to SOD1.Bcl-2 within or at the surface of the mitochondrion. Bcl-2
There are few data with which to judge this possibilityis a membrane protein anchored to the outer membrane
of the mitochondria in an Ncytosol-Cmitochondria orientation, at this time. However, the availability of mice and worms
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and 0.5% Triton X (v/v). Cells were incubated first with the anti-devoid of SOD1 should allow the design of experiments
Bcl-2 antibody (overnight, 4C) and then with the anti-SOD1 or Cox4to test this concept.
antibody (room temperature, for 60 min). Prior to addition of the
fluoro-labeled secondary antibodies, cells were washed three times
Experimental Procedures in PBS. Baseline decay times for FLIM were gathered as previously
described (Bacskai et al., 2003) by using the 488 fluorescein flouoro-
Cell Culture and Reagents phore attached to either the primary anti-Bcl-2 antibody or a fluores-
N2A cell cultures stably transfected with wt and mutant (G37R, cent secondary antibody. Decay times were measured using a
G41D, and G85R) SOD1 were grown in medium containing 50% multiphoton microscope (Radiance 2000, Bio-Rad) with a Ti:Saphire
DMEM, 50% OPTI-MEM, 7% fetal bovine serum, 1% antibiotic anti- laser (Tsunami, Spectra Physics) and a fast microchannel plate de-
mycotic, and 400 g/ml of the neomycin analog G418. Cells were tector (MCP; Hamamatsu, Bridgewater, NJ) connected to high-
harvested for co-immunoprecipitation experiments at 80% conflu- speed time correlated single photon counting (TCSPC) acquisition
ency. The anti-mouse Bcl-2 polyclonal antibody used for immuno- hardware (SPC-830; Becker & Hickl, Berlin) and data analyzed using
precipitation was obtained from Research Diagnostics, Inc. (RDI). a SPCImage software (Becker & Hickl). To investigate colocalization
The anti-mouse polyclonal antibody used for Western blot analysis between Bcl-2 and SOD1, spinal cord sections from human SOD1WT
was from Pharmingen. Antibodies used for immunoprecipitation and overexpressing mice were double labeled using secondary immunoflu-
Western blot analysis of human Bcl-2 were obtained from Biosource, oresence with fluorescein and Cy3 for Bcl-2 and SOD1, respectively.
Oncogene, and Santa Cruz. Rabbit anti-human SOD1 antibodies Images were collected using a Nikon Eclipse E800M microscope (Ni-
were from Biodesign and from Calbiochem. The anti-FLAG antibody kon, Mellville, NY) and Spot RT Software (Sterling Heights, MI).
was from Stratagene (La Jolla, CA). For FLIM analysis, fluorescein-
conjugated anti-hamster antibody and CyTM3-conjugated anti-rabbit
In Vitro Transcription-Translationsecondary antibodies were from Vector Laboratories (Burlingame,
Plasmids containing the T7 promoter were transcribed and trans-CA) and Jackson Immunoresearch Laboratories, respectively. Hu-
lated in reticulocytes lysates (TNT coupled system; Promega) follow-man Bcl-2 wt and mutant cDNAs were kindly provided by Dr. Stanley
ing the manufacturer’s instructions. When [35S]methionine was used,Korsmeyer (Dana Farber Institute, Boston, MA). The pcMV-FLAG-
proteins were translated for 1 hr in the presence of [35S]methionine.tag vector was from Stratagene. The TNT Quick Coupled Transcrip-
Reticulocyte lysates containing translated proteins were immuno-tion/Translation System used for in vitro transcription-translation of
precipiated using anti-human Bcl-2 antibodies or anti-human SOD1Bcl-2 and SOD1 was from Promega.
antibody, and immunoprecipitation was carried out as described
above. Immunoprecipitated proteins were resolved on SDS-PAGE,
Co-Immunoprecipitations transferred to nitrocellulose, and analyzed by Western blot analysis.
N2A cells were lysed in radio immunoprecipitation assay (RIPA) [35S]methionine radiolabeled proteins were visualized by autoradiog-
buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% NP-40, 12 mM raphy.
deoxycolic acid) containing proteases inhibitors (Boeringher Mann-
heim). After centrifugation (3500  g, 20 min, 4C), supernatants
Expression of Bcl-2 and SOD1 in Xenopus laevis Oocyteswere precleared for 8 hr at 4C with Biomag Protein A magnetic
The BH4 Bcl-2 deletion mutant and the BH4/loop Bcl-2 doublebeads (Qiagen, Valencia, CA). Rabbit anti-mouse Bcl-2 primary anti-
deletion mutant were subcloned into a pCMV-Tg4 vector (Stra-body (2.5 g) or rabbit anti-human SOD1 primary antibody (5 g)
tagene) containing a N-terminal FLAG and transcribed in vitro usingwere then added to the lysates and incubated overnight at 4C.
the mMessage mMachine Kit (Ambion). Linearized human SOD1 (wtThe antibody-antigen complex was then precipitated with Protein
and mutants) containing plasmids were similarly transcribed. StageA magnetic beads (4 hr, 4C, with rotation). Immunoprecipitates
V Xenopus laevis oocytes were enzymatically defolliculated, injectedwere washed three times with 200l of RIPA buffer, 20l of reducing
with bcl-2 cRNAs (20 ng/50 nl/oocyte) in combination with wt orsample buffer were added to the final pellet, and samples were
mutSOD1 cRNAs (20 ng/50 nl/oocyte), and maintained at 18C inboiled. Beads were pulled down using a magnet, supernatant was
L-15 solution (Specialty Media) supplemented with gentamycin sul-loaded on a 15% SDS-PAGE for electrophoresis, and Western blot
fate (100 g/ml). 3 days postinjection, oocytes were solubilized inanalysis was followed by enhanced chemiluminescence using the
RIPA buffer containing protease inhibitors; human Bcl-2 and humanAmersham ECL system.
SOD1 were co-immunoprecipitated using a monoclonal anti-FLAGFor immunoprecipitation of mouse or human spinal cord, samples
antibody (Stratagene). Proteins were resolved on SDS-PAGE, trans-were homogenized in RIPA buffer containing protease inhibitors and
ferred to nitrocellulose, and analyzed by Western immunoblotting.immunoprecipitation was carried out as described above. In the
human samples, an anti-human Bcl-2 antibody was used.
Mitochondria Isolation
Mouse and human liver and spinal cord were homogenized in BufferCrosslinking Analysis and Two-Dimension Electrophoresis
A containing 70 mM sucrose, 190 mM mannitol, 20 mM HEPES, andThe hydrophobic crosslinker DSP (Pierce, Rockford, IL; 5 mg/ml in
0.2 mM EDTA (pH 7.5) in a glass-Teflon pestle. The homogenateDMSO) was used. 1 mg of N2A cell lysates were incubated for 30
was centrifuged at 650  g for 10 min. The resulted supernatantmin at room temperature with 0, 0.5, or 2 mM DSP in a final volume
was centrifuged at 7700  g for 10 min. The resulted superna-of 500 l, buffered with PBS (pH 7.4). The reaction was stopped
tant was centrifuged at 100,000  g to collect the cytosolic fractionwith 1 M Tris-HCl, and 500 l of 2 nonreducing sample buffer were
while the pellet was resuspended in Buffer A and centrifuged againadded to each sample. Samples were boiled for 10 min prior to
at 7700 g for 10 min. The resulting mitochondrial pellet was resus-analysis in the first dimension SDS-PAGE. The position of high mo-
pended in 200 l of immunoprecipitation buffer containing prote-lecular mass complexes was analyzed in the first dimension by
ase inhibitors.Western blot analysis using antibodies to either mouse Bcl-2 or
human SOD1. First dimension lanes were excised from unstained,
unfixed gels, reduced in 	-mercapto-ethanol, and laid on top of the Acknowledgments
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